NCT05380154View on ClinicalTrials.gov

Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

January 22, 2018

Study Completion Date

July 6, 2018

Conditions
Glabellar Lines
Interventions
DRUG

Botulinum Toxin A type for injection (Botulax®)

Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects

DRUG

Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)

Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.

Trial Locations (1)

Unknown

Hugel Inc., Seoul

All Listed Sponsors
collaborator

Sihuan Pharmaceutical Limited

UNKNOWN

lead

Hugel

INDUSTRY

NCT05380154 - Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. | Biotech Hunter | Biotech Hunter